Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward P Armstrong

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|September 12, 2014
Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's diseaseJill M Augustine, Jeannie K Lee, Edward P Armstrong
Current Medical Research and Opinion|February 10, 2007
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorderEdward P Armstrong, Grant H Skrepnek, M Haim Erder
Journal of Pharmacy Practice|April 22, 2011
Skin cancer knowledge and prevention counseling among Arizona pharmacistsEdward P Armstrong, Charlotte Campbell, Ashley Van Allen, et al.
Pharmacy Practice|April 2, 2014
A pre- post-evaluation of implementing an inpatient warfarin monitoring and education programEdward P Armstrong, Lucy Chemodurow, Shanna Christensen, et al.
Current Medical Research and Opinion|February 10, 2007
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trialDaniel Ventura, Edward P Armstrong, Grant H Skrepnek, et al.
Current Medical Research and Opinion|April 2, 2005
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed careGrant H Skrepnek, Edward P Armstrong, Daniel C Malone, et al.
Best Practice & Research. Clinical Gastroenterology|November 5, 2013
Cost-effectiveness of biological agents used in ulcerative colitisJeannie K Lee, Derek H Tang, Lea Mollon, et al.
Journal of Medical Economics|August 12, 2014
Costs and utilization of hemophilia A and B patients with and without inhibitorsEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Toxicon : Official Journal of the International Society on Toxinology|September 24, 2013
Is scorpion antivenom cost-effective as marketed in the United States?Edward P Armstrong, Maja Bakall, Grant H Skrepnek, et al.
Hematology (Amsterdam, Netherlands)|July 9, 2014
Adherence to clotting factors among persons with hemophilia A or BEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Expert Review of Pharmacoeconomics & Outcomes Research|September 12, 2014
Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's diseaseJill M Augustine, Jeannie K Lee, Edward P Armstrong
Current Medical Research and Opinion|February 10, 2007
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorderEdward P Armstrong, Grant H Skrepnek, M Haim Erder
Journal of Pharmacy Practice|April 22, 2011
Skin cancer knowledge and prevention counseling among Arizona pharmacistsEdward P Armstrong, Charlotte Campbell, Ashley Van Allen, et al.
Pharmacy Practice|April 2, 2014
A pre- post-evaluation of implementing an inpatient warfarin monitoring and education programEdward P Armstrong, Lucy Chemodurow, Shanna Christensen, et al.
Current Medical Research and Opinion|February 10, 2007
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trialDaniel Ventura, Edward P Armstrong, Grant H Skrepnek, et al.
Current Medical Research and Opinion|April 2, 2005
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed careGrant H Skrepnek, Edward P Armstrong, Daniel C Malone, et al.
Best Practice & Research. Clinical Gastroenterology|November 5, 2013
Cost-effectiveness of biological agents used in ulcerative colitisJeannie K Lee, Derek H Tang, Lea Mollon, et al.
Journal of Medical Economics|August 12, 2014
Costs and utilization of hemophilia A and B patients with and without inhibitorsEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Toxicon : Official Journal of the International Society on Toxinology|September 24, 2013
Is scorpion antivenom cost-effective as marketed in the United States?Edward P Armstrong, Maja Bakall, Grant H Skrepnek, et al.
Hematology (Amsterdam, Netherlands)|July 9, 2014
Adherence to clotting factors among persons with hemophilia A or BEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Pageof 8